US › Healthcare

CytomX Therapeutics Inc (CTMX)

US · Healthcare · Biotechnology

$3.32+4.73%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$10.3M
Revenue YoY
-79.9%
Net profit
$-18.2M
Profit YoY
-177.6%
EPS
$-0.10
EPS estimate
$-0.11
Net margin
-177.9%

EPS came in at -0.10 against a street estimate of -0.11 — a beat of 9.1%.

Key statistics

Market cap
$674.9M
Forward P/E
14.2
P/B
2.11
Book value
$1.47
EPS (TTM)
$-0.52
52-week high
$8.21
52-week low
$1.72
50-day MA
$3.40
200-day MA
$4.19
Beta
2.08

Analyst view

Analysts rate CytomX Therapeutics Inc a buy (5 buy, 1 hold, 0 sell out of 6) with an average price target of $12.50.

Shareholding

Insiders
0.53%
Institutions
96.42%

Largest institutional holders

FundStake
FMR Inc14.68%
Kynam Capital Management, LP6.90%
Bank of America Corp4.69%
Perceptive Advisors LLC4.64%
VR Adviser, LLC4.59%
Vanguard Capital Management, LLC4.01%
Point72 Asset Management, L.P.3.62%
State Street Corp2.60%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for CytomX Therapeutics Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.